ClinicalTrials.gg
Active, not recruitingNCT04139902Updated Oct 20, 2026Results posted

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

A Phase 2 interventional study of Dostarlimab (TSR-042) (singly) and Dostarlimab (TSR-042) and TSR-022 (combination) in Melanoma Stage III and Melanoma Stage IV, sponsored by Diwakar Davar. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Diwakar Davar · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 20, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,050 studies in Melanoma with a site in United States — 242 open to participants now, 437 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
638th of 1,750
58 · median 37
Started
2020
with 83 others
Phase 2
613 of 2,050
47 open now
Primary completion
2025-09
later than 75 of 432 live
Registered
1,517th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 638th largest by enrollment of the 1,750 interventional ones that give a count, is one of 84 that started in 2020, is one of 613 in phase 2, reaches primary completion later than 75 of the 432 other live ones, and was the 1,517th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

242 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.

Read the detailed description

This is a randomized phase II neoadjuvant study comparing neoadjuvant therapy with PD-1 inhibitor Dostarlimab (TSR-042) to the PD-1/TIM-3 inhibitor combination Dostarlimab (TSR-042)/TSR-022 in patients with resectable regionally advanced or oligometastatic melanoma.

Patients with stage III B/C/D or oligometastatic stage IV A melanoma with lymph node (LN) and/or in-transit and/or oligometastatic disease who have yet to undergo definitive surgery are eligible to enroll.

Suitable patients will be identified pre-operatively. Patients will undergo screening evaluation consisting of systemic/CNS staging scans, tumor biopsy, blood studies to confirm suitability. Subjects will receive neoadjuvant therapy (Dostarlimab (TSR-042) or Dostarlimab (TSR-042)/TSR-022 combination for 6 weeks prior to planned surgery (pre-operative phase). Surgery will occur 1-4 weeks after completion of pre-operative therapy. After recovery from surgery subjects will receive Dostarlimab (TSR-042) (Post-Operative phase) for approximately 48 weeks; for a total of 54 weeks of study drug(s) administration in total.

In September of 2026, the outcome measures were updated to align with the current approved protocol and statistical analysis plan.

03

Conditions studied

  • Melanoma Stage III
  • Melanoma Stage IV

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • written for the study
  • ≥ 18 years of age
  • or cytologically confirmed diagnosis of cutaneous or unknown primary melanoma (excluding uveal/choroidal and mucosal melanoma; although acral melanoma is included) belonging to one of the following AJCC 8th edition TNM stages:

    1. Tx or T1-4 AND
    2. N1b, or N1c, or N2b, or N2c, or N3b, or N3c AND/OR
    3. M1a or M1b

Patients are eligible for this trial either at presentation for primary melanoma with concurrent regional nodal and/or in-transit and/or oligometastasis; AND/OR at the time of clinical detected nodal and/or in-transit and/or oligometastatic recurrence; and may belong to any of the following groups:

Primary melanoma with clinically apparent regional lymph node metastases; Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin; Clinically detected primary melanoma involving multiple regional nodal groups; Clinical detected nodal melanoma (if single site) arising from an unknown primary; In-transit and/or satellite metastases with or without regional lymph node involvement; Distant skin and/or in-transit and/or satellite metastases with or without regional lymph node involvement; Oligometastatic lung disease with or without regional lymph node involved permitted if deemed resectable at baseline NOTE: Determination of resectability must be made at baseline to be eligible for this study.

  • based on 1.1
  • must provide tumor tissue from a newly obtained core, punch, incisional or excisional tumor
  • 0 or 1 on the Performance Scale
  • Demonstrate adequate organ function on screening labs obtained within 14 days of registration
  • negative serum pregnancy test (females of )
  • females of non-childbearing potential must be ≥45 years of age and has not had menses for >1 year; if amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have an FSH value in the range; post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation (documented hysterectomy or oophorectomy)
  • male subjects should agree to use an adequate method of

Exclusion criteria

Exclusion Criteria:

  • Patients with uveal and/or mucosal melanoma histology are excluded (Patients with melanoma of unknown histology are permitted to enroll after discussion with Principal Investigator)
  • Is currently participating in or has participated in a study of an agent or using an investigational device within 4 weeks of the first dose of treatment.
  • Is receiving systemic with either (>10mg daily prednisone equivalent) or other immunosuppressive medications) for active disease: history of active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids (>10mg daily prednisone or equivalent) or systemic immunosuppressive agents
  • ≥ grade 3 immune-related AE (irAE) experienced with prior immunotherapy (except, non- lab abnormalities (elevations in lipase, amylase not associated with clinically significant disease etc.) even if ≥ CTCAE grade 3 may enroll if resolved at this time, or, development of autoimmune disorders of Grade ≤ 3 may enroll if the disorder has resolved to Grade ≤ 1)
  • received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (except ≤ Grade 2 neuropathy)
  • autoimmune disorders of Grade 4 while on prior immunotherapy
  • active (i.e., symptomatic or growing) central nervous system (CNS) and/or (CNS lesions that are treated and deemed stable (repeat imaging study done at least 2 weeks prior to first dose of study treatment) are NOT permitted to enroll even if other inclusion criteria are met and patients are neurologically asymptomatic)
  • known additional that is progressing or requires active treatment (except, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy)
  • invasive cancer diagnosed and treated less than 2 years prior to current presentation (other indolent malignancies that are not progressing and/or deemed to require active therapy are not exclusionary)
  • evidence of interstitial lung disease or active, non-infectious pneumonitis
  • active infection requiring systemic therapy
  • history or current evidence of any condition, therapy, or laboratory abnormality determined to be significant, in the opinion of the treating investigator
  • known psychiatric or substance abuse disorders that would interfere with study compliance
  • is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
  • had a within 30 days of initiating protocol therapy
  • received prior therapy with an IDO inhibitor, , anti-PD-L1, anti-PD-L2, anti-CD137 and/or combination (including nivolumab, pembrolizumab or ipilimumab/nivolumab). Prior treatment with ipilimumab or interferon alfa is allowed.
  • history of allergic or reaction to components or of Dostarlimab (TSR-042) and TSR-022, interferon alfa or ipilimumab
  • known history of (HIV) (HIV 1/2 antibodies).
  • known history of or screening test that is positive for virus (HBV; eg, HBsAg reactive or HBV DNA detected) or virus (HCV; HCV antibody positive and/or HCV RNA quantitative is detected). Hepatitis C antibody - positive subjects who received and completed treatment for hepatitis C that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable. Hepatitis B positive subjects who received and completed treatment for hepatitis B that was intended to eradicate the virus may participate if hepatitis B DNA levels are undetectable.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Dostarlimab (TSR-042) (singly)

    Pre-Operative Phase: Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1. Post-Operative Phase: Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks.

    Drug: Dostarlimab (TSR-042) (singly)

  • Experimental
    Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)

    Pre-Operative Phase: Dostarlimab (TSR-042) 500mg and Cobolimab TSR-022 300mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1. Post-Operative Phase: Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered.

    Drug: Dostarlimab (TSR-042) and TSR-022 (combination)

Interventions

  • DrugDostarlimabStudies of DostarlimabDostarlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1. Surgery will occur 1-4 weeks after completion of the pre-operative phase. During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks.

    Also known as: Dostarlimab

  • DrugDostarlimab (TSR-042) and TSR-022 (combination)

    Drug page: DostarlimabStudies of DostarlimabDostarlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1. Surgery will occur 1-4 weeks after completion of the pre-operative phase. During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks.

06

What researchers measure

Primary outcomes

  1. Major Pathologic Response (MPR)

    Percentage of patients with an RVT (residual volume of viable tumor) of ≤10% remaining in post-therapy specimen using immunotherapy-specific pathologic assessment of neoadjuvant treated melanoma specimens.

    Time frame: Time of Surgery (planned between 6-10 weeks from start of treatment)

Secondary outcomes

  1. Number of Participants Experiencing Adverse Events Attributed to Treatment

    Number of participants experiencing adverse events (per CTCAE v5.0) that are possibly, probably or definitely related to study treatment, will be tabulated by category, grade and relatedness. AEs will be collected for 30 days after the last dose of study therapy, but any SAEs occurring up to 90 days after the last dose of study therapy will additionally be recorded.

    Time frame: Up to 90 days after last dose of study therapy

  2. Frequency of Delays in Surgery

    Number of participants experiencing delays in their surgical procedures. A delay in surgery is defined as a surgery that occurs more than 6 weeks after completion of pre-operative therapy for reasons related to toxicity or progression.

    Time frame: Time of Surgery (planned between 6-10 weeks from start of treatment)

  3. Frequency of Cancellations of Surgery

    Number of participants experiencing a cancellation of their surgical procedure.

    Time frame: Time of Surgery (planned between 6-10 weeks from start of treatment)

  4. Relapse-free Survival

    The length of time from initiation of study drug(s) until melanoma relapse (disease progression) as defined by RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Up to 5 years from initiation of study treatment

  5. Overall Survival (OS)

    The length of time from initiation of study drug(s) that patients remain alive.

    Time frame: Up to 5 years from initiation of study treatment

Other outcomes

  1. Percentage of Circulating Immune Cells

    Percentage of immune cells present in circulating peripheral blood.

    Time frame: Up to 56 months

  2. Percentage of Intratumoral Immune Cells

    Percentage of immune cells present in tumor.

    Time frame: Up to 56 months

07

Results

Posted Oct 20, 2026

Participant flow

Pre-Operative
Participant flow — Pre-Operative
MilestoneDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
Started3028
Completed3028
Not completed00
Surgery
Participant flow — Surgery
MilestoneDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
Started3028
Completed3028
Not completed00
Post-Operative
Participant flow — Post-Operative
MilestoneDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
Started3028
Completed2928
Not completed10
Withdrew: Still on study treatment10

Outcome measures

PrimaryMajor Pathologic Response (MPR)

Percentage of patients with an RVT (residual volume of viable tumor) of ≤10% remaining in post-therapy specimen using immunotherapy-specific pathologic assessment of neoadjuvant treated melanoma specimens.

Time frame:
Time of Surgery (planned between 6-10 weeks from start of treatment)
Reported as:
Number · Percentage of Patients
Major Pathologic Response (MPR)
Percentage of PatientsDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
Major Pathologic Response (MPR)33.3 (17.3 to 52.8)53.6 (33.9 to 72.5)
SecondaryNumber of Participants Experiencing Adverse Events Attributed to Treatment

Number of participants experiencing adverse events (per CTCAE v5.0) that are possibly, probably or definitely related to study treatment, will be tabulated by category, grade and relatedness. AEs will be collected for 30 days after the last dose of study therapy, but any SAEs occurring up to 90 days after the last dose of study therapy will additionally be recorded.

Time frame:
Up to 90 days after last dose of study therapy

Results for this outcome have not been posted.

SecondaryFrequency of Delays in Surgery

Number of participants experiencing delays in their surgical procedures. A delay in surgery is defined as a surgery that occurs more than 6 weeks after completion of pre-operative therapy for reasons related to toxicity or progression.

Time frame:
Time of Surgery (planned between 6-10 weeks from start of treatment)
Reported as:
Count of participants · Participants
Frequency of Delays in Surgery
ParticipantsDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
Frequency of Delays in Surgery00
SecondaryFrequency of Cancellations of Surgery

Number of participants experiencing a cancellation of their surgical procedure.

Time frame:
Time of Surgery (planned between 6-10 weeks from start of treatment)
Reported as:
Count of participants · Participants
Frequency of Cancellations of Surgery
ParticipantsDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
Frequency of Cancellations of Surgery00
SecondaryRelapse-free Survival

The length of time from initiation of study drug(s) until melanoma relapse (disease progression) as defined by RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

Time frame:
Up to 5 years from initiation of study treatment

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

The length of time from initiation of study drug(s) that patients remain alive.

Time frame:
Up to 5 years from initiation of study treatment

Results for this outcome have not been posted.

Other pre-specifiedPercentage of Circulating Immune Cells

Percentage of immune cells present in circulating peripheral blood.

Time frame:
Up to 56 months

Results for this outcome have not been posted.

Other pre-specifiedPercentage of Intratumoral Immune Cells

Percentage of immune cells present in tumor.

Time frame:
Up to 56 months

Results for this outcome have not been posted.

Adverse events

Collected over AEs will be collected from the first dose of study treatment until 30 days after the last dose of study treatment for a total duration of up to 58 weeks. SAEs occurring up to 90 days after the last dose of study treatment will additionally be collected for a total duration of up to 67 weeks. All-cause mortality will be collected for up to 5 years from the first dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dostarlimab (TSR-042) (Singly)3/30 (10%)9/30 (30%)30/30 (100%)
Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)2/28 (7.1%)10/28 (35.7%)28/28 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
HyponatremiaMetabolism and nutrition disorders3/300/28
FeverGeneral disorders0/302/28
Thromboembolic EventVascular disorders0/302/28
Myocardial InfarctionCardiac disorders0/301/28
Abdominal PainGastrointestinal disorders0/301/28
PancreatitisGastrointestinal disorders0/301/28
Death NOSGeneral disorders0/301/28
Autoimmune DisorderImmune system disorders0/301/28
Wound InfectionInfections and infestations1/301/28
Creatinine IncreasedInvestigations1/301/28
Most frequent other events
Showing 10 of 94
Most frequent other events
EventDostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)
FatigueGeneral disorders17/3020/28
HyponatremiaMetabolism and nutrition disorders10/3015/28
Blood lactate dehydrogenase increasedInvestigations15/3013/28
Sinus bradycardiaCardiac disorders14/307/28
PainGeneral disorders11/3013/28
HyperglycemiaMetabolism and nutrition disorders9/3011/28
AnemiaBlood and lymphatic system disorders11/306/28
ParesthesiaNervous system disorders7/3010/28
CoughRespiratory, thoracic and mediastinal disorders4/3010/28
Rash maculo-papularSkin and subcutaneous tissue disorders10/3010/28

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)Total
Mean67.1 ± 12.863.4 ± 13.665.3 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Dostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)Total
Female9918
Male211940
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White222648
More than one race000
Unknown or Not Reported819
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)Total
Hispanic or Latino000
Not Hispanic or Latino232548
Unknown or Not Reported7310
Location of Tumor at Study Entry
Location of Tumor at Study Entry(Participants)Dostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)Total
Axilla5914
Groin448
Head/Neck131023
Lower Extremity336
Other202
Trunk224
Upper Extremity101
Nature of Tumor
Nature of Tumor(Participants)Dostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)Total
In-transit202
Lymph Node141933
Other12820
Satellite011
Unknown202
Prior Systemic Cancer Therapy
Prior Systemic Cancer Therapy(Participants)Dostarlimab (TSR-042) (Singly)Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination)Total
No272653
Yes325
08

Study locations

5 sites
09

References and documents

Publications

  • Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2. PubMed 36648215 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Sep 2025, 63 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 63 months is close to that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Oct 25, 2019
StartActual
Jun 12, 2020
Primary completionActual
Sep 29, 2025
CompletionEst.
Dec 15, 2029
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Enrollment
48→58
Oct 20, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameMajor Pathologic Response (MPR)5 years (for population) → Time of Surgery (planned between 6-10 weeks from start of treatment)
  • DescriptionMajor Pathologic Response (MPR): how it is measured was reworded
Oct 20, 2026
Documents
Secondary outcomes
2 edited, 5 time frame changed, 3 description edited
What changed in the outcomes
  • Time frameNumber of Participants Experiencing Adverse Events Attributed to TreatmentUp to 56 months → Up to 90 days after last dose of study therapy
  • Time frameFrequency of Delays in SurgeryUp to 56 months → Time of Surgery (planned between 6-10 weeks from start of treatment)
  • Time frameFrequency of Cancellations of SurgeryUp to 56 months → Time of Surgery (planned between 6-10 weeks from start of treatment)
  • Time frameRelapse-free SurvivalUp to 56 months → Up to 5 years from initiation of study treatment
  • Time frameOverall Survival (OS)Up to 56 months → Up to 5 years from initiation of study treatment
  • DescriptionFrequency of Cancellations of Surgery: how it is measured was reworded
  • DescriptionFrequency of Delays in Surgery: how it is measured was reworded
  • DescriptionNumber of Participants Experiencing Adverse Events Attributed to Treatment: how it is measured was reworded
  • Editedother outcomePercentage of Circulating immune cellsImmune CellsTime frame: Up to 56 months
  • Editedother outcomePercentage of Intratumoral immune cellsImmune CellsTime frame: Up to 56 months
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Enrollment 48→58
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameMajor Pathologic Response (MPR)5 years (for population) → Time of Surgery (planned between 6-10 weeks from start of treatment)
    • DescriptionMajor Pathologic Response (MPR): how it is measured was reworded
    Secondary outcomes 2 edited, 5 time frame changed, 3 description edited
    What changed in the outcomes
    • Time frameNumber of Participants Experiencing Adverse Events Attributed to TreatmentUp to 56 months → Up to 90 days after last dose of study therapy
    • Time frameFrequency of Delays in SurgeryUp to 56 months → Time of Surgery (planned between 6-10 weeks from start of treatment)
    • Time frameFrequency of Cancellations of SurgeryUp to 56 months → Time of Surgery (planned between 6-10 weeks from start of treatment)
    • Time frameRelapse-free SurvivalUp to 56 months → Up to 5 years from initiation of study treatment
    • Time frameOverall Survival (OS)Up to 56 months → Up to 5 years from initiation of study treatment
    • DescriptionFrequency of Cancellations of Surgery: how it is measured was reworded
    • DescriptionFrequency of Delays in Surgery: how it is measured was reworded
    • DescriptionNumber of Participants Experiencing Adverse Events Attributed to Treatment: how it is measured was reworded
    • Editedother outcomePercentage of Circulating immune cellsImmune CellsTime frame: Up to 56 months
    • Editedother outcomePercentage of Intratumoral immune cellsImmune CellsTime frame: Up to 56 months
    + 3 other changes: verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04139902
Lead sponsor
Diwakar Davar
Collaborators
Tesaro, Inc.
Responsible party
Diwakar Davar (Assistant Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Oct 25, 2019
Start date
Jun 12, 2020
Primary completion
Sep 29, 2025
Completion
Dec 15, 2029 (estimated)
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Diwakar Davar, MD
principal investigator · UPMC Hillman Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion